National Institutes of Health

InVivo Biosystems specializes in early biological and biomedical research by utilizing alternative, non-mammalian model organisms. The company develops and commercializes proprietary systems for the genetic modification of simple microscopic living animals, such as C. elegans and zebrafish, through its transgenic platform. These organisms serve as human proxies for disease research and drug discovery, helping researchers gain insights into genetic mutations and human health. InVivo Biosystems offers essential services to pharmaceutical, biotechnology, and academic institutions worldwide, aiming to accelerate their research and drug development efforts. The company's mission focuses on enhancing the understanding of high-impact disorders, including Alzheimer’s disease, epilepsy, and cancer, by providing an affordable and accessible research platform that facilitates mutant phenotyping, drug screening, and toxicological assessments.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Resvita Bio is engaged in the development and manufacturing of engineered probiotics aimed at treating skin-related diseases, including chronic conditions and cancer. The company focuses on creating a versatile skin microbial platform utilizing synthetic biology and metabolic engineering. This innovative approach allows for the continuous delivery of therapies that alleviate inflammation, promote tissue regeneration, and eliminate harmful bacteria. By leveraging this technology, Resvita Bio aims to offer faster and more efficient treatment alternatives for individuals suffering from chronic skin diseases.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

Matter Bio is a biotechnology company dedicated to preserving genome integrity and enhancing longevity through the preservation of DNA information. The company aims to address the critical issue of information loss in the genome by assembling a team of expert scientists and executives. By focusing on mutation reversal, Matter Bio seeks to empower patients with the potential to improve their health and extend their lifespan. Through its innovative research services, the company strives to advance the understanding and application of genetic preservation techniques.

Phenomix Sciences is a biotechnology company founded in 2017 and headquartered in New York, United States. It specializes in the fields of metabolomics and genomics, focusing on developing healthcare solutions for personalized management of chronic diseases. The company has created a data analysis platform aimed at precision medicinal research for obesity management, which features a novel blood test and an AI-driven algorithm. This platform classifies the unique pathophysiological phenotype of patients with obesity, providing healthcare centers with tools and services that enhance the efficacy of obesity management while also reducing side effects and overall costs.

InVivo Biosystems specializes in early biological and biomedical research by utilizing alternative, non-mammalian model organisms. The company develops and commercializes proprietary systems for the genetic modification of simple microscopic living animals, such as C. elegans and zebrafish, through its transgenic platform. These organisms serve as human proxies for disease research and drug discovery, helping researchers gain insights into genetic mutations and human health. InVivo Biosystems offers essential services to pharmaceutical, biotechnology, and academic institutions worldwide, aiming to accelerate their research and drug development efforts. The company's mission focuses on enhancing the understanding of high-impact disorders, including Alzheimer’s disease, epilepsy, and cancer, by providing an affordable and accessible research platform that facilitates mutant phenotyping, drug screening, and toxicological assessments.

RNAConnect specializes in developing enzymatic tools for visualizing and manipulating RNA, with a focus on low-abundance and long, structured RNAs. Their core product is a reverse transcriptase designed to provide greater visibility into these challenging RNA types and their various isoforms. This enzyme is optimized to synthesize cDNA with high fidelity and processivity, enabling researchers to study complex RNA template structures without the need for heat.

Neurodon Corporation is focused on discovering and developing disease-modifying therapies for intractable diseases by addressing endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach utilizes first-in-class modulators to restore calcium levels in cells, enabling the creation of therapeutics for conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and diabetes. Founded in 2019 and based in Crown Point, Indiana, Neurodon has advanced two candidates into IND-enabling studies, with plans to commence clinical trials in 2025. The company has raised over $11 million through various funding sources, including grants and partnerships, and is currently seeking additional funding to support its upcoming clinical studies. Neurodon’s unique platform technology positions it as a leader in addressing diseases linked to ER stress, with no direct competitors targeting the same mechanism of action.

Golden Helix specializes in bioinformatics solutions that enhance life science research and translational medicine. With over 20 years of experience, the company offers innovative technologies and analytic services designed to help scientists and healthcare professionals interpret vast amounts of genomic data generated from microarrays and next-generation sequencing. Their cloud-based software efficiently manages, analyzes, and visualizes complex genomic and phenotypic datasets. By streamlining the processes of annotating and filtering variants, Golden Helix empowers biologists and researchers to conduct sophisticated analyses and visualizations independently, reducing the reliance on bioinformatics experts.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

The Buck Institute is the nation’s first independent research facility focused solely on understanding the connection between aging and chronic disease. Their mission is to increase the healthy years of life. At the Buck Institute, world-class scientists work in a uniquely collaborative environment to understand how normal aging contributes to the development of conditions specifically associated with getting older such as Alzheimer’s and Parkinson’s diseases, cancer, stroke, osteoporosis, heart disease, diabetes, macular degeneration and glaucoma. Their interdisciplinary approach brings scientists from disparate fields together to develop diagnostic tests and treatments to prevent or delay these maladies. The stakes have never been higher. While it’s true that people are living longer, those “extra” years are often marked by disability and pain. In addition to personal hardship, there is also a cost to society. The financial burden of treating the chronic diseases of aging is expected to rise steadily as Baby Boomers get older. There is an urgency to Their mission.

Talus Bio is a biotech startup focused on drug discovery, particularly in the development of therapies targeting gene regulators for cancer treatment. The company utilizes a data-enabled platform that combines functional proteomics, automated biology, and machine learning to address the challenges associated with cancer transcription factors. Its proprietary MARMOT platform employs advanced techniques such as AI, quantitative proteomics, synthetic chemistry, and computational biology to design and analyze small-molecule drugs and proteins. This innovative approach aims to enhance drug development processes in the oncology sector, facilitating advancements in gene regulation and contributing to more effective cancer therapies.

Inherent Biosciences is a molecular diagnostics company focused on transforming the trial and error approach in medicine by leveraging insights from epigenetics. The company aims to provide clarity on complex health issues by identifying dysregulation across multiple genes and pathways, which informs personalized treatment strategies. Inherent Biosciences develops innovative therapies for a range of conditions, including pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. By translating biological discoveries into actionable insights, the company seeks to enhance patient care and improve outcomes in various medical fields.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

The Mount Sinai School of Medicine in New York, New York, one of the only schools in the nation with a distinctive Department of Medical Education that continually improves the quality of its teaching, offers students a variety of medical academics to shape them into compassionate assistants, professionals and industry leaders. The academics available at Mount Sinai include master's and PhD programs in areas like: * Science and Medicine * Patient Oriented Research Training and Leadership * Biomedical Sciences * Genetic Counseling * Clinical Research Besides its degree-granting programs, Mount Sinai also offers an extensive number of residencies and fellowships, some of which include: * Anesthesiology * Cardiology * Dental Medicine * Emergency Medicine * Hematology and Oncology College life at Mount Sinai is fully-immersed in the medical sciences. All your instruction, provided by medical professionals, will be delivered in a hospital setting, allowing you to familiarize yourself with the many resources and technology used in today's hospitals. Mount Sinai is also home to the Levy Library, which is fully-stocked with myriad medical resources, from journals to professional magazines to textbooks. Since each program has different admissions requirements, please contact Mount Sinai for more information on a program that interests you and your career goals. Tuition assistance is available to students through fellowship programs and Mount Sinai grants and scholarships. For more information federal sources of financial aid, please contact an aid advisor from the school.

Sequentify is a biotechnology company that develops innovative solutions for targeted DNA sequencing applications, including cancer diagnostics, carrier screening, and COVID-19 surveillance. By integrating synthetic biology with artificial intelligence software, the company offers alternative library-preparation methods that facilitate rapid and cost-effective genome sequencing. This technology empowers researchers to conduct genomic diagnostics and therapeutics on a large scale, thus enhancing the efficiency and accessibility of genomic analysis in various health-related fields.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Allen Institute for Brain Science is a non-profit medical research organization dedicated to understanding the complexities of bioscience. The organization encompasses three entities, the Allen Institute for Brain Science, Allen Institute for Cell Science, and Paul G. Allen Frontiers Group. Its mission is to accelerate the understanding of how the brain works in health and disease. It creates useful public resources, drive technological and analytical advances, and discover fundamental brain properties through integration of experiments using a big science, team science, and open science approach. Allen Institute for Brain Science was founded on 2003 and is based in Seattle, Washington.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Oligomerix, Inc. is a biopharmaceutical company based in Bronx, New York, founded in 2006. It specializes in developing therapeutics for Alzheimer’s disease and related neurodegenerative disorders through innovative research on tau proteins. The company focuses on small molecule drug discovery, specifically targeting tau oligomers and developing tau protease inhibitors. In addition to small molecules, Oligomerix is involved in creating antibody fragments that serve as biomarkers to aid in drug development, diagnostics, and therapeutic applications. By leveraging its novel approaches to generate stable amyloid oligomers, Oligomerix aims to enhance target identification and validation, contributing to improved treatment options for various tauopathies, including progressive supranuclear palsy and frontotemporal dementia.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Talus Bio is a biotech startup focused on drug discovery, particularly in the development of therapies targeting gene regulators for cancer treatment. The company utilizes a data-enabled platform that combines functional proteomics, automated biology, and machine learning to address the challenges associated with cancer transcription factors. Its proprietary MARMOT platform employs advanced techniques such as AI, quantitative proteomics, synthetic chemistry, and computational biology to design and analyze small-molecule drugs and proteins. This innovative approach aims to enhance drug development processes in the oncology sector, facilitating advancements in gene regulation and contributing to more effective cancer therapies.

Genomenon, Inc. is a software development company based in Ann Arbor, Michigan, that specializes in tools for genetic diagnosis and discovery. Founded in 2014, it provides a suite of diagnostic and discovery solutions that enable physicians, researchers, and pharmaceutical companies to rapidly and accurately identify disease-causing variants from genomic sequencing data. The company’s flagship product, GENOMENON, automates the analysis of next-generation sequencing data, thereby enhancing decision-making processes in clinical settings and accelerating discoveries in genomics. With its focus on improving cancer diagnosis and treatment, Genomenon aims to support better patient outcomes through its innovative software solutions.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cell and gene therapies aimed at treating hematologic cancers, solid tumors, and rare genetic diseases. The company has a diverse pipeline that includes gene therapy programs for rare genetic disorders and various chimeric antigen receptor (CAR) T cell therapies targeting both hematologic malignancies and solid tumors. Notable projects include MB-107, a gene therapy aimed at treating X-linked severe combined immunodeficiency, which is currently undergoing Phase 1/2 clinical trials. Other therapies under development include MB-102 for acute myeloid leukemia, MB-106 for B-cell lymphomas, and multiple CAR T programs targeting glioblastoma, prostate cancer, and pancreatic cancer. Mustang Bio also collaborates with institutions such as Nationwide Children’s Hospital and Beth Israel Deaconess Medical Center for research and development in gene editing and oncolytic viruses. Established in 2015 and headquartered in New York, Mustang Bio operates as a subsidiary of Fortress Biotech, Inc.

Amplo Biotechnology is focused on developing innovative Adeno-Associated Viral (AAV) therapies aimed at addressing severe diseases related to the neuromuscular junction, which can lead to paralysis, breathing difficulties, and swallowing challenges. The company targets conditions such as congenital myasthenic syndromes, leveraging its lead program, AAV-Dok7, developed by a research group at the University of Tokyo. The therapies are administered through intravascular injections, initiating molecular processes that enable effective treatment for patients suffering from these rare disorders. Amplo’s mission is to create potentially curative solutions for conditions that significantly impact patient health and quality of life.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Nanoscope Therapeutics Inc. specializes in developing innovative gene therapies aimed at restoring vision for individuals suffering from retinal degenerative diseases, including retinitis pigmentosa and dry age-related macular degeneration. Founded in 2017 and based in Bedford, Texas, the company employs light-sensitive molecules and light-assisted gene delivery techniques to target and treat specific areas of the retina. This approach allows for the re-sensitization of retinal cells to low light levels, enabling patients to regain some degree of vision. Nanoscope's therapeutic platform focuses on providing effective solutions for vision loss, addressing a significant unmet need in the field of ocular health.

ID Genomics is focused on nucleotide sequence-based molecular diagnostics and epidemiological analysis of microbial pathogens. The company offers high-resolution clonal identification suitable for both large and small-scale applications in clinical microbiology, reference, and academic research laboratories. Utilizing expanded multi-locus sequence typing (MLST) and genome-wide polymorphism annotation, ID Genomics provides customized phylogenetic and genomic analyses, along with database creation. Their diagnostic system integrates molecular diagnostics with epidemiological surveillance and big data tools, enabling rapid matching of infecting pathogens to appropriate treatments. This approach allows healthcare providers to make informed antibiotic choices quickly, enhancing personalized treatment for infectious diseases and ultimately improving patient outcomes.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally created at Cornell University, the company specializes in high-efficiency processing of cellular material. Inso Biosciences aims to enhance applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. Their platform facilitates the separation and isolation of cellular components, thereby supporting healthcare and biotech companies in their biological sample preparation needs.

AvantGen is a biotechnology company based in San Diego, established in 2006, that specializes in therapeutic antibody discovery and optimization. The company operates two divisions: Therapeutic and Research & Diagnostic. Its Therapeutic Division focuses on the discovery of novel human antibodies, antibody humanization, and affinity maturation to enhance therapeutic development. AvantGen utilizes a proprietary yeast display system and maintains a large natural human antibody database, along with fully human antibody libraries and advanced screening technologies. The company's innovative platform also includes methodologies for rabbit monoclonal antibody generation and cell engager technology. AvantGen collaborates with pharmaceutical and biotechnology firms, offering services and licensing agreements to expedite the development of antibody-based therapeutics.

HDT Bio is a clinical-stage biotechnology company focused on developing RNA vaccines and therapeutics to combat infectious diseases and cancer. Utilizing its innovative LION formulation technology, the company creates ribonucleic acid-based products that enhance the delivery and stability of nucleic acids through various administration routes. HDT Bio’s offerings include self-amplifying RNA vaccines and innate immune agonist therapeutics, which aim to activate innate immunity, amplify adaptive immune responses, and disrupt tumor tight junctions. The company's mission is to advance immunotherapy technologies in a cost-effective manner, addressing critical healthcare needs in both developed and low- to middle-income countries, particularly in the fight against some of the world's most dangerous infectious diseases.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Coral Genomics, Inc. is a biotechnology company based in San Francisco, California, founded in 2018. The company specializes in optimizing drug development and deployment through the use of genomic data derived from patients. Coral Genomics focuses on creating new clinical tests that assist healthcare providers in streamlining prior authorization processes and selecting effective medications tailored to individual patients, particularly those with autoimmune conditions such as Inflammatory Bowel Disease and Rheumatoid Arthritis. Additionally, the company has identified a distinct population of non-responder patients and collaborates with drug developers to address their unmet medical needs.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Phase Genomics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing innovative technology for genome assembly and metagenome deconvolution, focusing on its ProxiMeta Hi-C platform. This platform empowers researchers in various fields, including agriculture, human health, and industrial biology, by enabling the cultivation-independent assembly of bacterial genomes. By exploiting the structure of DNA, Phase Genomics aims to provide scientists with the most complete and accurate genomes and metagenomes possible, facilitating transformative discoveries and advancements in their respective areas of study.

Lactiga is a biotherapeutics company focused on developing innovative treatments for infections, particularly for patients with Primary Immunodeficiency Diseases. By harnessing the therapeutic properties of human milk, Lactiga aims to create biologics that prevent mucosal infections associated with conditions such as selective IgA deficiency and common variable immunodeficiency. The company’s mission is to enhance the quality of life for immunodeficient and immunocompromised individuals, allowing them to lead more normal lives without relying on invasive therapies. Through its groundbreaking research, Lactiga is addressing significant health challenges posed by dangerous pathogens.

Neurodon Corporation is focused on discovering and developing disease-modifying therapies for intractable diseases by addressing endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach utilizes first-in-class modulators to restore calcium levels in cells, enabling the creation of therapeutics for conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and diabetes. Founded in 2019 and based in Crown Point, Indiana, Neurodon has advanced two candidates into IND-enabling studies, with plans to commence clinical trials in 2025. The company has raised over $11 million through various funding sources, including grants and partnerships, and is currently seeking additional funding to support its upcoming clinical studies. Neurodon’s unique platform technology positions it as a leader in addressing diseases linked to ER stress, with no direct competitors targeting the same mechanism of action.

Mesa Biotech, Inc. is a company focused on designing, developing, and manufacturing molecular diagnostic tests for infectious diseases. Founded in 2015 and based in San Diego, California, with a satellite laboratory in Santa Fe, New Mexico, Mesa Biotech has created a range of products, including the Accula Dock and various Accula test cassettes for influenza and respiratory syncytial virus. The company utilizes innovative technology that simplifies DNA and RNA testing, combining the convenience of rapid point-of-care tests with the sensitivity and specificity typically associated with laboratory-based molecular diagnostics. This approach allows healthcare professionals to obtain actionable, laboratory-quality results quickly and efficiently.

Helix is a prominent population genomics company that focuses on the convergence of clinical care, research, and genomics. Its comprehensive platform assists health systems, life sciences companies, and payers in advancing genomic research and integrating genomic data into clinical practice. Helix operates one of the world's largest CLIA/CAP-certified next-generation sequencing labs and utilizes its proprietary Exome+ assay to support various aspects of population genomics, including participant recruitment, disease screening, result reporting, and both basic and translational research.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing innovative CRISPR solutions for a variety of applications. The company offers DETECTR™, a diagnostic platform that identifies specific nucleic acids in samples, aiding in the detection of diseases such as bacterial infections, cancer, and viral infections. Additionally, Mammoth Biosciences provides CRISPR-Cas systems for genome editing, targeting therapeutic areas including immuno-oncology, autoimmune diseases, and liver diseases. By harnessing proprietary ultracompact proteins and leveraging advanced research and development, Mammoth aims to create affordable point-of-care tests and enhance diagnostics across healthcare, agriculture, and environmental monitoring. Co-founded by CRISPR pioneer Jennifer Doudna, the company has attracted significant investment from institutional and individual backers.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Fauna Bio Incorporated is a biotechnology company based in San Francisco, California, founded in 2018. It specializes in developing a cross-mammal drug discovery platform aimed at treating human diseases, including heart disease and neurodegenerative disorders. By studying the mechanisms that allow certain animals, such as hibernating and deep-diving species, to withstand extreme conditions, Fauna Bio seeks to uncover insights that can enhance human health. The company utilizes animal genomics, transcriptomics, metabolomics, and proteomics data from a diverse range of species to identify novel drug targets and facilitate pre-clinical and early clinical testing of new therapeutics. Through its innovative approach, Fauna Bio aims to improve recovery from serious medical events like trauma, heart attacks, and strokes.

DiamiR is mission is to build a leading molecular diagnostics company focused on developing minimally invasive solutions for early detection and monitoring of brain and synaptic health conditions, including mild cognitive impairment and Alzheimer’s disease, to enable earlier intervention and better planning of care.

SciBac Inc. develops innovative live biotherapeutics aimed at treating antibiotic-resistant diseases while strengthening the microbiome. Founded in 2015 and located in Milpitas, California, the company utilizes a patented MERGE platform that employs directed evolution to enhance the efficacy of beneficial microorganisms. SciBac's initial therapeutics focus on chronic infections associated with cystic fibrosis, targeting pathogens such as Pseudomonas, Staphylococcus, Burkholderia, and non-tuberculous mycobacteria (NTM). By safely transferring beneficial genetic traits, SciBac's approach aims to promote rapid recovery and minimize the risk of reinfections, thereby improving treatment outcomes for patients facing these challenging infections.

Gencove is a software platform that focuses on high-throughput and cost-effective genome sequencing through the use of low-pass sequencing technology. The company aims to revolutionize genomics research and diagnostics across various species by providing fast and affordable whole-genome sequencing solutions. Gencove develops both molecular and computational tools that facilitate low-cost genome sequencing, making genomic data accessible to researchers in diverse industries, including agriculture and pharmaceuticals.

Precision Virologics, Inc. is a biotechnology company focused on developing biologically targeted vaccines for emerging infectious diseases, including Zika. Established in 2016 and headquartered in Saint Louis, Missouri, the company utilizes an innovative technology based on adenoviral vectors that incorporate camelid antibodies aimed at activated dendritic cells. This approach allows for the precise delivery of proprietary antigen epitopes to target pathogens and offers significant advantages, such as reduced cross-reactivity among flaviviruses and enhanced potency. In addition to its Zika vaccine candidate, PV-ZIKV, Precision Virologics also aims to address other infectious diseases, including chikungunya and dengue, by harnessing its advanced vaccine development capabilities.

The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium of individual volunteers and a small dedicated staff who are interested in facilitating use of pharmacogenetic tests for patient care. One barrier to implementation of pharmacogenetic testing in the clinic is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for affected drugs. CPIC’s goal is to address this barrier to clinical implementation of pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines (click here for all CPIC publications). CPIC guidelines follow standardized formats, include systematic grading of evidence and clinical recommendations, use standardized terminology, are peer-reviewed, and are published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to cpicpgx.org, where they are regularly updated.

Salk Institute for Biological Studies conducts research on molecular biology and genetics, neurosciences, and plant biology. The research is conducted under the guidance of 59 faculty investigators and more than 850 scientific staff, including visiting scientists, postdoctoral fellows, and graduate students. The institute’s operates to identify therapies and treatments for a range of diseases such as cancer, AIDS, Alzheimer's disease, cardiovascular disorders, anomalies of the brain, and birth defects. Six key areas represent strategic research priorities: chemistry and proteomics, stem cell biology, cell biology, regulatory biology, metabolic research, and computational and theoretical biology. The Institute has trained more than 2,700 scientists, out of which five have won Nobel prizes. Salk is home to nine Howard Hughes Medical Investigators and 14 members of the National Academy of Sciences. NCI Cancer Center, Crick-Jacobs Center, Glenn Center for Aging Research, Helmsley Center for Genomic Medicine, Waitt Advanced Biophotonics Center, and Glenn Center for Aging Research are some of the research centers operated by Salk Institute for Biological Studies. The Salk Institute for Biological Studies was established in the 1960s by Jonas Salk and is based in California, United States.

Quadrant Biosciences Inc. is a life sciences company focused on developing epigenetic diagnostic solutions and biomarker technologies aimed at addressing significant healthcare challenges, particularly in the early identification of neurological disorders such as Autism Spectrum Disorder, concussion, and Parkinson's Disease. Founded in 2015 and based in Syracuse, New York, the company has established collaborative research relationships with various institutions to explore innovative diagnostic and therapeutic solutions. Quadrant Biosciences leverages its expertise in RNA analysis to enhance healthcare delivery and has also contributed to addressing health issues related to the COVID-19 pandemic. The company aims to improve lives through its commitment to advancing molecular diagnostic tools.

Precision Virologics, Inc. is a biotechnology company focused on developing biologically targeted vaccines for emerging infectious diseases, including Zika. Established in 2016 and headquartered in Saint Louis, Missouri, the company utilizes an innovative technology based on adenoviral vectors that incorporate camelid antibodies aimed at activated dendritic cells. This approach allows for the precise delivery of proprietary antigen epitopes to target pathogens and offers significant advantages, such as reduced cross-reactivity among flaviviruses and enhanced potency. In addition to its Zika vaccine candidate, PV-ZIKV, Precision Virologics also aims to address other infectious diseases, including chikungunya and dengue, by harnessing its advanced vaccine development capabilities.

Celldom, Inc. is a research tools company based in Durham, North Carolina, established in 2016. It specializes in single-cell analysis technology aimed at enhancing research, drug discovery, and development by revealing the diversity within cell populations. The company's flagship product, the TrapTx Analyzer System, integrates phenotypic and genomic data on a large scale, allowing for the identification and characterization of rare cells that are crucial in various biological pathways and diseases. Celldom focuses on applications in oncology, immunology, and stem cell biology, providing innovative solutions that enable researchers to automate the analysis of cellular heterogeneity effectively.

Neurodon Corporation is focused on discovering and developing disease-modifying therapies for intractable diseases by addressing endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach utilizes first-in-class modulators to restore calcium levels in cells, enabling the creation of therapeutics for conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and diabetes. Founded in 2019 and based in Crown Point, Indiana, Neurodon has advanced two candidates into IND-enabling studies, with plans to commence clinical trials in 2025. The company has raised over $11 million through various funding sources, including grants and partnerships, and is currently seeking additional funding to support its upcoming clinical studies. Neurodon’s unique platform technology positions it as a leader in addressing diseases linked to ER stress, with no direct competitors targeting the same mechanism of action.

Mission Bio, Inc. is a biotechnology company that specializes in tools for studying cellular heterogeneity in human health and life sciences. The company has developed the Tapestri Platform, the first single-cell multi-omics platform, which allows for the simultaneous analysis of genotype and phenotype from the same cell. This platform utilizes proprietary microfluidic droplet technology to enable precise detection of genomic variability at single-cell resolution, facilitating research in various applications, including oncology, blood cancers, solid tumors, and genome editing. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating customized single-cell DNA panels, further enhancing its capabilities in targeted molecular analysis. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.

Phase Genomics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing innovative technology for genome assembly and metagenome deconvolution, focusing on its ProxiMeta Hi-C platform. This platform empowers researchers in various fields, including agriculture, human health, and industrial biology, by enabling the cultivation-independent assembly of bacterial genomes. By exploiting the structure of DNA, Phase Genomics aims to provide scientists with the most complete and accurate genomes and metagenomes possible, facilitating transformative discoveries and advancements in their respective areas of study.

Intact Genomics is a biotechnology research and development company specializing in large DNA fragment cloning and metagenomic technologies. Located in the Helix Center Biotech Incubator near prominent institutions such as Monsanto and the Donald Danforth Plant Science Center in St. Louis, the company utilizes advanced equipment and employs dedicated scientists to provide a range of life science products and services. Intact Genomics focuses on large insert DNA cloning, manipulation, and bacterial artificial chromosome library services, facilitating scientists' exploration of the genome structure and function across various microorganisms, plants, and animal species.

Scripps Translational Science Institute works to translate the latest advances in genomics into new diagnostics and treatments. In collaboration with Scripps Genomic Medicine, STSI researchers have collected DNA to generate a comprehensive human DNA bank. These samples could help identify genetic markers for cardiovascular disease, breast, colon and prostate cancers. and other conditions. STSI and Scripps Genomic Medicine investigators have also partnered with Affymetrix, Microsoft, and Navigenics to determine whether personal genomic testing motivates people to make positive lifestyle changes.

Scripps Research, established in 1924, is a prominent, not-for-profit biomedical research institution with campuses in La Jolla, CA, and Jupiter, FL. Employing around 3,000 people, it's renowned for its contributions to science and health, including breakthroughs in cancer, rheumatoid arthritis, and hemophilia treatments. The institute, which ranks among the top ten for its graduate program in biology and chemistry, is led by distinguished scientists, including Nobel laureates. Its drug discovery and development division, Calibr, collaborates with scientists to expedite the delivery of innovative medicines to patients. Scripps Research is recognized as a leader in biomedical innovation, ranking No.1 by the Nature Index.

Sangamo Therapeutics is a clinical-stage biotechnology company focused on developing genomic therapies aimed at transforming the lives of patients with serious health conditions. The company employs advanced technologies in genome editing, gene therapy, gene regulation, and cell therapy to create innovative treatment options. Sangamo's diverse product pipeline addresses a range of diseases, including hemophilia, various central nervous system disorders, HIV, lysosomal storage disorders, and hemoglobinopathies. Additionally, the company has prioritized neurology-related programs targeting chronic neuropathic pain, prion disease, and other neurological conditions. Other ongoing initiatives involve treatments for Fabry disease, renal transplant, inflammatory bowel disease, and multiple sclerosis, reflecting Sangamo's commitment to addressing critical unmet medical needs.

SolveBio specializes in genomic intelligence, providing a platform that facilitates the integration and management of genomic data for pharmaceutical, biotech, and diagnostic organizations. By enabling these entities to connect and utilize both internal and external genomic information, SolveBio supports innovation in precision medicine and advances human health. The platform allows clients to access and distribute genomic reference data at scale, creating a dynamic interface that enhances the use of third-party information assets. This approach empowers organizations to drive discovery and improve decision-making in the rapidly evolving field of genomics.

Allen Institute for Brain Science is a non-profit medical research organization dedicated to understanding the complexities of bioscience. The organization encompasses three entities, the Allen Institute for Brain Science, Allen Institute for Cell Science, and Paul G. Allen Frontiers Group. Its mission is to accelerate the understanding of how the brain works in health and disease. It creates useful public resources, drive technological and analytical advances, and discover fundamental brain properties through integration of experiments using a big science, team science, and open science approach. Allen Institute for Brain Science was founded on 2003 and is based in Seattle, Washington.

Scripps Research, established in 1924, is a prominent, not-for-profit biomedical research institution with campuses in La Jolla, CA, and Jupiter, FL. Employing around 3,000 people, it's renowned for its contributions to science and health, including breakthroughs in cancer, rheumatoid arthritis, and hemophilia treatments. The institute, which ranks among the top ten for its graduate program in biology and chemistry, is led by distinguished scientists, including Nobel laureates. Its drug discovery and development division, Calibr, collaborates with scientists to expedite the delivery of innovative medicines to patients. Scripps Research is recognized as a leader in biomedical innovation, ranking No.1 by the Nature Index.

The Jackson Laboratory, established in 1929 and headquartered in Bar Harbor, Maine, with a facility in California, specializes in mammalian genetics research. It provides international laboratories with scientific services and genetic resources, while also educating students through courses, internships, and collaborative programs. The company's primary focus is discovering the genetic basis for preventing, treating, and curing human diseases across various areas such as cancers, immunology, metabolic diseases, and neurobiology. Additionally, it offers comprehensive mouse breeding and research services tailored to the mouse-based biomedical research community, including breeding management, cryopreservation, phenotyping, and study-ready induced models.

Circulomics is a biotechnology company based in Maryland, operating within the IMET's Harbor Launch Incubator. The company has secured nearly $8 million in funding from the National Institutes of Health and Maryland TEDCO to create advanced platforms for nucleic acid sample preparation, microRNA profiling, and single molecule analysis. These innovations aim to enhance the research and clinical applications of genomics technologies, facilitating processes from sequencing to expression profiling and biomarker analysis. Circulomics has developed a single molecule analysis system that optimizes the genomics workflow, improving sample characterization prior to sequencing and critical studies, thereby supporting cancer diagnosis and analysis.

The Jackson Laboratory, established in 1929 and headquartered in Bar Harbor, Maine, with a facility in California, specializes in mammalian genetics research. It provides international laboratories with scientific services and genetic resources, while also educating students through courses, internships, and collaborative programs. The company's primary focus is discovering the genetic basis for preventing, treating, and curing human diseases across various areas such as cancers, immunology, metabolic diseases, and neurobiology. Additionally, it offers comprehensive mouse breeding and research services tailored to the mouse-based biomedical research community, including breeding management, cryopreservation, phenotyping, and study-ready induced models.

Genomenon, Inc. is a software development company based in Ann Arbor, Michigan, that specializes in tools for genetic diagnosis and discovery. Founded in 2014, it provides a suite of diagnostic and discovery solutions that enable physicians, researchers, and pharmaceutical companies to rapidly and accurately identify disease-causing variants from genomic sequencing data. The company’s flagship product, GENOMENON, automates the analysis of next-generation sequencing data, thereby enhancing decision-making processes in clinical settings and accelerating discoveries in genomics. With its focus on improving cancer diagnosis and treatment, Genomenon aims to support better patient outcomes through its innovative software solutions.

Circulomics is a biotechnology company based in Maryland, operating within the IMET's Harbor Launch Incubator. The company has secured nearly $8 million in funding from the National Institutes of Health and Maryland TEDCO to create advanced platforms for nucleic acid sample preparation, microRNA profiling, and single molecule analysis. These innovations aim to enhance the research and clinical applications of genomics technologies, facilitating processes from sequencing to expression profiling and biomarker analysis. Circulomics has developed a single molecule analysis system that optimizes the genomics workflow, improving sample characterization prior to sequencing and critical studies, thereby supporting cancer diagnosis and analysis.

Celldom, Inc. is a research tools company based in Durham, North Carolina, established in 2016. It specializes in single-cell analysis technology aimed at enhancing research, drug discovery, and development by revealing the diversity within cell populations. The company's flagship product, the TrapTx Analyzer System, integrates phenotypic and genomic data on a large scale, allowing for the identification and characterization of rare cells that are crucial in various biological pathways and diseases. Celldom focuses on applications in oncology, immunology, and stem cell biology, providing innovative solutions that enable researchers to automate the analysis of cellular heterogeneity effectively.

23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.

Scripps Research, established in 1924, is a prominent, not-for-profit biomedical research institution with campuses in La Jolla, CA, and Jupiter, FL. Employing around 3,000 people, it's renowned for its contributions to science and health, including breakthroughs in cancer, rheumatoid arthritis, and hemophilia treatments. The institute, which ranks among the top ten for its graduate program in biology and chemistry, is led by distinguished scientists, including Nobel laureates. Its drug discovery and development division, Calibr, collaborates with scientists to expedite the delivery of innovative medicines to patients. Scripps Research is recognized as a leader in biomedical innovation, ranking No.1 by the Nature Index.

Inova Translational Medicine Institute (ITMI) is a not-for-profit research institute focused on utilizing genomic and clinical data to advance personalized healthcare. As part of the Inova Center for Personalized Health, ITMI fosters collaboration among researchers, clinicians, and consumers to integrate genomic research into patient care, prevention, and wellness strategies. This innovative approach aims to shift healthcare from a reactive model to a predictive one, enhancing longevity and improving health outcomes. ITMI conducts research that generates extensive genomic and clinical datasets, which are valuable for various fields, including computational biology, psychology, and biomedical research. By analyzing genomic information, ITMI seeks to understand disease onset and promote preventative medicine, thereby enhancing treatment efficacy and minimizing adverse reactions.

Coriell Institute for Medical Research, founded in 1953 and based in Camden, New Jersey, is an independent non-profit research center dedicated to the study of the human genome. Expert staff and pioneering programs in the fields of personalized medicine, cell biology, cytogenetics, genotyping, and biobanking drive Their mission. The emerging field of personalized medicine draws upon a person’s genomic information to tailor treatments and prescription drug dosing to optimize health outcomes. The Coriell Personalized Medicine Collaborative (CPMC) research study is seeking to understand the usefulness of genetic risk and pharmacogenomics in clinical decision-making and healthcare management.

Intact Genomics is a biotechnology research and development company specializing in large DNA fragment cloning and metagenomic technologies. Located in the Helix Center Biotech Incubator near prominent institutions such as Monsanto and the Donald Danforth Plant Science Center in St. Louis, the company utilizes advanced equipment and employs dedicated scientists to provide a range of life science products and services. Intact Genomics focuses on large insert DNA cloning, manipulation, and bacterial artificial chromosome library services, facilitating scientists' exploration of the genome structure and function across various microorganisms, plants, and animal species.

ID Genomics is focused on nucleotide sequence-based molecular diagnostics and epidemiological analysis of microbial pathogens. The company offers high-resolution clonal identification suitable for both large and small-scale applications in clinical microbiology, reference, and academic research laboratories. Utilizing expanded multi-locus sequence typing (MLST) and genome-wide polymorphism annotation, ID Genomics provides customized phylogenetic and genomic analyses, along with database creation. Their diagnostic system integrates molecular diagnostics with epidemiological surveillance and big data tools, enabling rapid matching of infecting pathogens to appropriate treatments. This approach allows healthcare providers to make informed antibiotic choices quickly, enhancing personalized treatment for infectious diseases and ultimately improving patient outcomes.

TetraGenetics, Inc. is a biotechnology company focused on developing therapeutic proteins and vaccines for the biopharmaceutical industry. Established in 2004 and based in Arlington, Massachusetts, the company utilizes its proprietary TetraExpress system to produce recombinant human ion channel proteins and other complex biologics. TetraGenetics specializes in the production of eukaryotic membrane and secretory proteins, which are often difficult to express using conventional systems. Among its products is IchVax, a recombinant subunit vaccine aimed at preventing white-spot disease in freshwater fish. The company is also engaged in a strategic research and development collaboration with Imbrium Therapeutics L.P., aiming to address autoimmune diseases and provide solutions for ion channel-related conditions. TetraGenetics' technology enables rapid production of properly folded, functional transmembrane proteins, positioning the company as a valuable player in the development of novel therapeutics and vaccines for both human and animal health.

Stemina Biomarker Discovery, Inc. is a company based in Madison, Wisconsin, that specializes in the discovery and development of human cellular models for toxicity screening. Founded in 2006, the company focuses on assessing the safety of drug candidates, chemical compounds, and cosmetic ingredients through innovative biomarker-based assays. Its notable offerings include the Cardio quickPredict assay, which evaluates the cardiotoxicity potential of compounds using human induced pluripotent stem cell-derived cardiomyocytes, and the devTOX quickPredict assay, designed to predict developmental toxicity through human embryonic stem cells. Additionally, Stemina engages in collaborative research to develop molecular biomarkers for disease diagnosis and personalized treatment, utilizing metabolomics and mass spectrometry to analyze how human cells respond to various substances. The company's work aims to enhance drug safety and improve human health outcomes.

The Vermont Genetics Network (VGN) is funded by a five-year, $16.5 million award from the National Center for Research Resources (NCRR), and is part of a National Institutes of Health (NIH) initiative called IDeA Networks of Biomedical Research Excellence (INBRE). Under the direction of Dr. Judith Van Houten, the VGN, which links scientists at Castleton State College, Johnson State College, Middlebury College, Norwich University and St. Michael's College to resources at UVM, is designed to provide funding for research, equipment and technology necessary to enhance competitiveness for national funding for genetics research. Other aims of the project include increasing the number of undergraduates who go on to biomedical careers from the baccalaureate colleges, to provide and support bioinformatics capability in the state, and to increase the diversity of biomedical scientists.

Scripps Research, established in 1924, is a prominent, not-for-profit biomedical research institution with campuses in La Jolla, CA, and Jupiter, FL. Employing around 3,000 people, it's renowned for its contributions to science and health, including breakthroughs in cancer, rheumatoid arthritis, and hemophilia treatments. The institute, which ranks among the top ten for its graduate program in biology and chemistry, is led by distinguished scientists, including Nobel laureates. Its drug discovery and development division, Calibr, collaborates with scientists to expedite the delivery of innovative medicines to patients. Scripps Research is recognized as a leader in biomedical innovation, ranking No.1 by the Nature Index.

Codagenix, Inc. is a biotechnology company specializing in the development of live-attenuated viral vaccines targeting various diseases, including influenza, dengue, respiratory syncytial virus, and polio. Founded in 2009 and based in Farmingdale, New York, the company leverages its innovative Synthetic Attenuated Virus Engineering (SAVE) platform, which employs computer-based rational design to re-engineer the genomes of viruses. This technology enables the creation of vaccines that incorporate specific target antigens within an attenuated viral backbone. In addition to human vaccines, Codagenix also develops vaccines for agricultural and companion animals, contributing to a broader approach to viral disease management.

Igenica, Inc. is a biotherapeutic company based in Burlingame, California, dedicated to the discovery and development of antibodies and antibody-drug conjugates (ADCs) for cancer treatment. Founded in 2008, Igenica specializes in immunotherapies and functional antibodies designed to target tumors effectively. The company's notable products include IGN523, a humanized monoclonal antibody aimed at treating various hematologic and solid tumors; IGN786, an ADC; and IGN381, which targets immune checkpoints that complement existing therapies in the tumor microenvironment. Igenica has established a strategic oncology research agreement with MedImmune and is supported by a group of prominent life science investors, including The Column Group and OrbiMed. The company operates as a subsidiary of Pierre Fabre Medicament SA, with a leadership team that has significant experience in antibody drug discovery and commercialization.

23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.

The J. Craig Venter Institute is a prominent organization in genomic research, established in October 2006 through the merger of several institutions, including The Institute for Genomic Research and The Center for the Advancement of Genomics. With over 400 scientists and staff, the Institute operates from two primary locations in Rockville, Maryland, and San Diego, California, encompassing more than 250,000 square feet of laboratory space. The Institute's research initiatives span a wide range of topics, including genomic medicine, infectious diseases, mammalian genomics, microbial and environmental genomics, and synthetic biology. Notable achievements include the sequencing of the first free-living organism and significant contributions to the human genome project. Recent projects have involved sequencing microbial flora in human environments and discovering millions of new genes from ocean sampling expeditions. The Institute is also actively engaged in creating synthetic organisms and studying the evolution of infectious disease agents, aiming to enhance understanding and treatment of various diseases affecting global health.

Oligomerix, Inc. is a biopharmaceutical company based in Bronx, New York, founded in 2006. It specializes in developing therapeutics for Alzheimer’s disease and related neurodegenerative disorders through innovative research on tau proteins. The company focuses on small molecule drug discovery, specifically targeting tau oligomers and developing tau protease inhibitors. In addition to small molecules, Oligomerix is involved in creating antibody fragments that serve as biomarkers to aid in drug development, diagnostics, and therapeutic applications. By leveraging its novel approaches to generate stable amyloid oligomers, Oligomerix aims to enhance target identification and validation, contributing to improved treatment options for various tauopathies, including progressive supranuclear palsy and frontotemporal dementia.

Akonni Biosystems, Inc. is a biotechnology company based in Frederick, Maryland, specializing in molecular diagnostics. Founded in 2003, the company develops and manufactures integrated diagnostic systems aimed at clinical and life science research markets. Its key product, the TruDiagnosis platform, allows for point-of-care testing of infectious diseases, while TruTip kits assist in DNA and RNA extraction. The company also offers TruArray tests for multiplexed molecular diagnostics, which analyze clinical samples such as blood, saliva, and urine. Akonni's technology is utilized in diagnosing a range of conditions, including infectious diseases, oncology, and genetic disorders. Their innovative systems leverage advanced methods like 3D gel drop microarray technology for effective detection of various health-related targets.

The Jackson Laboratory, established in 1929 and headquartered in Bar Harbor, Maine, with a facility in California, specializes in mammalian genetics research. It provides international laboratories with scientific services and genetic resources, while also educating students through courses, internships, and collaborative programs. The company's primary focus is discovering the genetic basis for preventing, treating, and curing human diseases across various areas such as cancers, immunology, metabolic diseases, and neurobiology. Additionally, it offers comprehensive mouse breeding and research services tailored to the mouse-based biomedical research community, including breeding management, cryopreservation, phenotyping, and study-ready induced models.

Circulomics is a biotechnology company based in Maryland, operating within the IMET's Harbor Launch Incubator. The company has secured nearly $8 million in funding from the National Institutes of Health and Maryland TEDCO to create advanced platforms for nucleic acid sample preparation, microRNA profiling, and single molecule analysis. These innovations aim to enhance the research and clinical applications of genomics technologies, facilitating processes from sequencing to expression profiling and biomarker analysis. Circulomics has developed a single molecule analysis system that optimizes the genomics workflow, improving sample characterization prior to sequencing and critical studies, thereby supporting cancer diagnosis and analysis.

Regenxbio Inc. is a clinical-stage biotechnology company focused on developing gene therapy products to address genetic disorders and enable cells to produce therapeutic proteins and antibodies. The company leverages its proprietary NAV Technology Platform, which utilizes adeno-associated virus vectors for gene delivery. Regenxbio's lead product candidate, RGX-314, is under investigation in a Phase I/IIa clinical trial for wet age-related macular degeneration. Other notable product candidates include RGX-121 and RGX-111, which are in clinical trials for mucopolysaccharidosis type II and I, respectively, as well as RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia. Additionally, Regenxbio licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and collaborates with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.

Natera, Inc. is a diagnostic and research company specializing in genetic testing services, particularly in the areas of preconception and prenatal diagnostics. Founded in 2003 and headquartered in San Carlos, California, Natera offers a range of products including the Panorama non-invasive prenatal test, which screens for chromosomal abnormalities in fetuses, and Vistara, a test for single-gene mutations. Additionally, the company provides Horizon carrier screening to assess carrier status for various genetic diseases, and Spectrum, which analyzes genetic conditions during in vitro fertilization. Natera's Anora product analyzes fetal chromosomes to understand miscarriage causes, while its non-invasive paternity tests determine parentage through fetal DNA analysis. The company's Signatera technology focuses on circulating tumor DNA to monitor cancer recurrence. Natera distributes its products through a direct sales force and a network of approximately 100 laboratory and distribution partners, both domestically and internationally. The company collaborates with BGI Genomics to develop genetic testing assays and has partnered with Foundation Medicine for personalized cancer monitoring assays.

Akonni Biosystems, Inc. is a biotechnology company based in Frederick, Maryland, specializing in molecular diagnostics. Founded in 2003, the company develops and manufactures integrated diagnostic systems aimed at clinical and life science research markets. Its key product, the TruDiagnosis platform, allows for point-of-care testing of infectious diseases, while TruTip kits assist in DNA and RNA extraction. The company also offers TruArray tests for multiplexed molecular diagnostics, which analyze clinical samples such as blood, saliva, and urine. Akonni's technology is utilized in diagnosing a range of conditions, including infectious diseases, oncology, and genetic disorders. Their innovative systems leverage advanced methods like 3D gel drop microarray technology for effective detection of various health-related targets.